Seeking Alpha

Uncommon Profit Investor

 
(In beta) Send Us Feedback»
Title Symbol Long/
Short
Date of
publication
3m from
publication
6m from
publication
1y from
publication
Ominous Signs For Valeant In The Allergan Q2 Earnings Call AGN Short
7/23/2014
6.3%
-
-
Who Is Telling The Truth On Fillers: Valeant's CEO Or Allergan's CEO? Is Valeant's Debt A Time-Bomb? VRX Short
6/23/2014
-4.3%
-
-
Allergan Should Buy Perrigo For A Tax Inversion; Before Someone Else Does AGN Long
6/20/2014
1.7%
-
-
Valeant Left Important Questions Unanswered; Allergan Shareholders Beware AGN Short
6/18/2014
4.7%
-
-
Perrigo Can Reach $200 If It Keeps Tysabri Royalties, Lot More If It Sells Them PRGO Long
6/11/2014
2.9%
-
-
Valeant Bulls Don't Understand This Accounting Trick, Allergan Shareholders Need To; A Tutorial On Capitalizing Vs. Expensing AGN Short
6/3/2014
0.4%
-
-
Why Allergan Should Reject Valeant AGN Short
6/2/2014
-1.9%
-
-
Investor's Guide To Valeant's May 28 Event For Allergan And Valeant Shareholders AGN Long
5/27/2014
-1.4%
-
-
Catalyst For Perrigo: Sale Of Tysabri Royalties PRGO Long
5/22/2014
9.1%
-
-
Buy Allergan, Not Valeant. It's A No-Brainer. AGN Long
5/14/2014
-2.6%
-
-
Allergan Can Buy Perrigo To Avoid Valeant AGN Long
5/11/2014
-3.9%
-
-
Valeant's Low Returns On Capital And Other Problems VRX Short
4/30/2014
-5.9%
-1.6%
-